OmniAb (OABI) Cash & Equivalents (2021 - 2026)
OmniAb's (OABI) quarterly Cash & Equivalents came in at $29.0 million in Q1 2026, up 166.67% year-on-year from $10.9 million in Q1 2025, and up 44.65% on a QoQ basis from $20.1 million in Q4 2025.
OmniAb (OABI) Cash & Equivalents (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Cash & Equivalents data on file, last reported at $29.0 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 166.67% year-over-year to $29.0 million in Q1 2026; TTM through Mar 2026 was $29.0 million, a 166.67% increase from a year earlier, with the FY2025 full-year figure at $20.1 million, down 27.24% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $29.0 million, up from $20.1 million in the prior quarter.
- Over the last five years, Cash & Equivalents for OABI reached as high as $33.4 million in Q4 2022 and fell as low as $19847.0 in Q3 2022.
- Historically, Cash & Equivalents has averaged $18.6 million across 5 years, with a median of $20.8 million in 2024.
- Across the five-year window, Cash & Equivalents slumped 94.52% in 2022 and surged 106943.89% in 2023, its largest moves.
- Year by year, Cash & Equivalents stood at $33.4 million in 2022, then tumbled by 51.01% to $16.4 million in 2023, then surged by 68.71% to $27.6 million in 2024, then decreased by 27.24% to $20.1 million in 2025, then jumped by 44.65% to $29.0 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $29.0 million in Q1 2026, $20.1 million in Q4 2025, and $28.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | 29.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.05 Mn |
| Dec 31, 2025 | 20.08 Mn |
| Sep 30, 2025 | 28.54 Mn |
| Jun 30, 2025 | 18.28 Mn |
| Mar 31, 2025 | 10.89 Mn |
| Dec 31, 2024 | 27.60 Mn |
| Sep 30, 2024 | 27.24 Mn |
| Jun 30, 2024 | 20.79 Mn |
| Mar 31, 2024 | 19.06 Mn |
| Dec 31, 2023 | 16.36 Mn |
| Sep 30, 2023 | 21.25 Mn |
| Jun 30, 2023 | 20.99 Mn |
| Mar 31, 2023 | 22.91 Mn |
| Dec 31, 2022 | 33.39 Mn |
| Sep 30, 2022 | 19,847.00 |
| Jun 30, 2022 | 159,194.00 |
| Mar 31, 2022 | 434,629.00 |
| Sep 30, 2021 | 362,203.00 |
| Jun 30, 2021 | 36,145.00 |